STOCK TITAN

LeMaitre Vascular (LMAT) Stock News, Nov 2021-Apr 2022

LMAT NASDAQ

LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.

Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.

News
Rhea-AI Summary

LeMaitre (NASDAQ: LMAT) reported its Q1 2022 results, highlighting a sales increase of $39.6 million, up 10% year-over-year. Operating income remained flat at $7.9 million with a 20% operating margin. The company announced a quarterly dividend of $0.125 per share and provided updated guidance for 2022, forecasting sales of $160-$164 million. Key developments included a buyout of its Korean distributor and the closure of its St. Etienne factory, expected to reduce future operating costs. However, the strong U.S. dollar negatively impacted both sales and operating income guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q1 2022 financial results on April 28, 2022, post-market. A conference call is scheduled for 5:00 PM ET to discuss the results and company outlook. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company develops and markets both disposable and implantable vascular devices targeted at vascular surgeons. Further details can be found at www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that Chief Financial Officer JJ Pellegrino will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 10:15 AM ET. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company focuses on developing disposable and implantable vascular devices tailored for vascular surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) has been added to the NASDAQ US Broad Dividend Achievers Index, recognizing companies with a decade of increasing dividends. Since initiating dividends in 2011, LeMaitre's payout per share rose from $0.08 to $0.44 in 2021, achieving an 18.6% compounded annual growth rate. A new quarterly dividend of $0.125 will be distributed on March 24, 2022. CEO George W. LeMaitre emphasized the company's commitment to profitability and an improved balance sheet through consistent dividend increases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
dividends
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four significant investor conferences this March. The 34th Annual Roth Conference is scheduled for March 14, 2022, with President David Roberts presenting. Following that, the Oppenheimer 32nd Annual Healthcare Conference takes place on March 16, 2022, featuring CFO JJ Pellegrino. On March 17, 2022, Roberts will present at the Barclays Global Healthcare Conference, and the month concludes with the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) reported Q4 2021 sales of $39.5 million, a 5% increase year-over-year, driven by higher sales of bovine grafts and patches. Operating income fell 13% to $8.3 million, with an operational margin of 21%. The company announced a 14% increase in its quarterly dividend to $0.125 per share, marking the 11th consecutive year of dividend growth. For Q1 2022, guidance suggests sales between $37.7 million and $39.7 million, with a gross margin of 66.2%. Full-year 2022 guidance anticipates sales of $162 million to $166 million, aiming for an EPS of $1.35 to $1.45.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary

LeMaitre Vascular, Inc. (LMAT) will release its fourth quarter 2021 financial results on February 24, 2022, after market close. A conference call is scheduled for 5:00 PM ET that day to discuss the results and company outlook. The company provides devices and services for peripheral vascular disease, affecting over 200 million people globally. Investors can access the live call by dialing 800-773-2954 or through a webcast on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
-
Rhea-AI Summary

LeMaitre Vascular announced that CFO JJ Pellegrino will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:30 AM ET. The company specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. More information is available at www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the 24th Annual Needham Virtual Growth Conference on January 14, 2022, at 3:30 PM. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops a range of disposable and implantable vascular devices aimed at meeting the needs of vascular surgeons. Additional details are available on their website at www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) has announced participation in three upcoming virtual investor conferences:

  • Stifel 2021 Virtual Healthcare Conference – November 15, 2021, 8:40 AM ET (David Roberts, President)
  • Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – November 18, 2021 (JJ Pellegrino, CFO)
  • Piper Sandler 33rd Virtual Annual Healthcare Conference – November 29 – December 2, 2021 (Pre-recorded presentation by David Roberts)

LeMaitre specializes in medical devices for peripheral vascular disease, serving over 200 million affected patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.40%
Tags
conferences

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

LeMaitre Vascular (LMAT) last closed at $74.86.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately $1.7B.